within Pharmacolibrary.Drugs.ATC.C;

model C07AA15
  extends Pharmacokinetic.Models.PK_1C_enteral(
    weight         = 70,
    F              = 0.85,
    Cl             = 0.005,
    adminDuration  = 600,
    adminMass      = 10 / 1000000,   // mg → kg
    adminCount     = 1,
    Vd             = 0.0035,
    Cmin           = 0.001,
    Cmax           = 0.01,
    Ctox_peak      = 0.02,
    Ctox_trough    = 0.01,
    ka             = 0.0009166666666666666,
    Tlag           = 600
  );

  annotation (Documentation(
    info       = "<html><body><table><tr><td>Drug:</td><td>C07AA15</td></tr><td>route:</td><td>oral</td></tr><tr><td>n-compartments</td><td>1</td></tr></table><p>Carteolol is a non-selective beta-adrenergic antagonist (beta blocker) used primarily for the treatment of hypertension, angina pectoris, and glaucoma (in topical form). It is approved for these conditions and is marketed in several countries, often most commonly as ophthalmic drops for glaucoma.</p><h4>Pharmacokinetics</h4><p>Pharmacokinetic parameters reported for healthy adult volunteers, following single oral administration.</p><h4>References</h4><ol><li><p>Ishizaki, T, et al., &amp; Suganuma, T (1983). Pharmacokinetics and absolute bioavailability of carteolol, a new beta-adrenergic receptor blocking agent. <i>European journal of clinical pharmacology</i> 25(1) 95–101. DOI:<a href=\"https://doi.org/10.1007/BF00544023\">10.1007/BF00544023</a>  PUBMED:<a href=\"https://pubmed.ncbi.nlm.nih.gov/6137389/\">https://pubmed.ncbi.nlm.nih.gov/6137389</a></p></li><li><p>Hasenfuss, G, et al., &amp; Just, H (1985). Pharmacokinetics of carteolol in relation to renal function. <i>European journal of clinical pharmacology</i> 29(4) 461–465. DOI:<a href=\"https://doi.org/10.1007/BF00613462\">10.1007/BF00613462</a>  PUBMED:<a href=\"https://pubmed.ncbi.nlm.nih.gov/4092726/\">https://pubmed.ncbi.nlm.nih.gov/4092726</a></p></li><li><p>Morita, S, et al., &amp; Kori, H (1977). [Metabolic fate of carteolol hydrochloride (OPC-1085), a new beta-adrenergic blocking agent. (6) Pharmacokinetics of carteolol in the rat, dog, rabbit and man]. <i>Nihon yakurigaku zasshi. Folia pharmacologica Japonica</i> 73(2) 229–235. DOI:<a href=\"https://doi.org/10.1254/fpj.73.229\">10.1254/fpj.73.229</a>  PUBMED:<a href=\"https://pubmed.ncbi.nlm.nih.gov/328355/\">https://pubmed.ncbi.nlm.nih.gov/328355</a></p></li></ol></body></html>",
    revisions  = "<html><body><ul><li>06/2025 initial model generated by LLM gpt-4.1 from general data</li></ul></body></html>"
  ));
end C07AA15;
